MAPK3 and left ventricular hypertrophy: We show here that sorafenib exhibits a regulatory role on the occurrence of left ventricular hypertrophy by blocking the rise in growth factors, and activation of the corresponding c-Raf-ERK1/2 signaling pathway and effector mechanisms including ANP production.